📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Tumour suppressor EP300, a modulator of paclitaxel resistance and stemness, is downregulated in metaplastic breast cancer. (2017)

First Author: Asaduzzaman M

Attributed to: Targeting the FOXM1 signature for early diagnosis and treatment in cholangiocarcinoma funded by Newton Fund

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1007/s10549-017-4202-z

PubMed Identifier: 28341962

Publication URI: http://europepmc.org/abstract/MED/28341962

Type: Journal Article/Review

Volume: 163

Parent Publication: Breast cancer research and treatment

Issue: 3

ISSN: 0167-6806